Home / NRXS : AMEX

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does NRXS make money? Does NRXS have pricing power? What's the Earnings Whisper? Will NRXS profit more as the business scales? What is NRXS's management track record? Is NRXS's current price justified?

NeurAxis, Inc.

$5.74 +$1.28 (+28.70%)

AMEX · 11 Sep 2026 20:00 UTC

Previous Close

$5.69

Day Range

$5.64$5.77

Year Range

$2.21$9.33

Market Cap

71.62M

AVG Volume

117.9K

Trailing/Forward PE

-7.45/-

PEG ratio

0.12

Dividend Yield

Next Earnings Date

2026-11-17

Primary Exchange

New York Stock Exchange Arca

Revenue (USD)

NRXS Revenue (USD) by quarter
Period	Revenue (USD)
26 Q2	1.93M
26 Q1	1.61M
25 Q4	968.13K
25 Q3	811.41K
25 Q2	894.09K
25 Q1	895.65K
24 Q4	761.16K
24 Q3	666.62K
24 Q2	611.5K
24 Q1	646.63K

Net Income (USD)

NRXS Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-2.28M
26 Q1	-1.76M
25 Q4	-1.71M
25 Q3	-2.12M
25 Q2	-1.69M
25 Q1	-2.28M
24 Q4	-1.45M
24 Q3	-1.76M
24 Q2	-2.92M
24 Q1	-2.12M

Operating Income (USD)

NRXS Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-2.12M
26 Q1	-1.74M
25 Q4	-1.72M
25 Q3	-2.1M
25 Q2	-1.72M
25 Q1	-2.3M
24 Q4	-1.47M
24 Q3	-1.65M
24 Q2	-2.21M
24 Q1	-1.83M

EBITDA (USD)

NRXS EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-2.05M
26 Q1	-1.72M
25 Q4	-1.66M
25 Q3	-2.08M
25 Q2	-1.66M
25 Q1	-2.27M
24 Q4	-1.44M
24 Q3	-1.64M
24 Q2	-2.76M
24 Q1	-2.06M

Cash Flows (USD)

NRXS Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-1.04M
26 Q1	-1.23M
25 Q4	-1.94M
25 Q3	-1.43M
25 Q2	-1.47M
25 Q1	-1.62M
24 Q4	-1.76M
24 Q3	-1.4M
24 Q2	-1.62M
24 Q1	-1.35M

EPS (USD)

NRXS EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.19
26 Q1	-0.18
25 Q4	-0.16
25 Q3	-0.24
25 Q2	-0.22
25 Q1	-0.33
24 Q4	-0.24
24 Q3	-0.25
24 Q2	-0.42
24 Q1	-0.32

Expenses (USD)

NRXS Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	3.79M
26 Q1	3.13M
25 Q4	2.55M
25 Q3	2.78M
25 Q2	2.47M
25 Q1	3.07M
24 Q4	2.12M
24 Q3	2.23M
24 Q2	2.75M
24 Q1	2.42M

Cash & Debt (USD)

NRXS Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	8.32M
26 Q1	7.08M
25 Q4	4.97M
25 Q3	4.38M
25 Q2	5.99M
25 Q1	2.01M
24 Q4	3.7M
24 Q3	260.88K
24 Q2	1.77M
24 Q1	81.75K

Debt ratios

NRXS Debt ratios by quarter
Period	Debt ratios
26 Q2	1.07
26 Q1	0.95
25 Q4	0.59
25 Q3	0.52
25 Q2	0.79
25 Q1	0.2
24 Q4	0.41
24 Q3	-0.02
24 Q2	-0.19
24 Q1	-0.11

Margins

NRXS Margins by quarter
Period	Margins
26 Q2	85.87%
26 Q1	86.42%
25 Q4	85.4%
25 Q3	83.3%
25 Q2	83.6%
25 Q1	84.43%
24 Q4	86.2%
24 Q3	85.44%
24 Q2	87.99%
24 Q1	88.39%

Return on Capital

NRXS Return on Capital by quarter
Period	Return on Capital
26 Q2	-33.81%
26 Q1	-30.65%
25 Q4	-50.26%
25 Q3	-92.9%
25 Q2	-39.74%
25 Q1	-881.57%
24 Q4	-70.02%
24 Q3	97.84%
24 Q2	55.49%
24 Q1	66.59%

Shares Outstanding

NRXS Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	12.12M
26 Q1	10.95M
25 Q4	9.08M
25 Q3	9.88M
25 Q2	8.52M
25 Q1	7.46M
24 Q4	6.92M
24 Q3	6.98M
24 Q2	6.92M
24 Q1	6.55M

Book Value Per Share (USD)

NRXS Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	0.56
26 Q1	0.52
25 Q4	0.37
25 Q3	0.23
25 Q2	0.5
25 Q1	0.03
24 Q4	0.3
24 Q3	-0.26
24 Q2	-0.76
24 Q1	-0.49

Total Assets (USD)

NRXS Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	10M
26 Q1	8.75M
25 Q4	6.4M
25 Q3	5.78M
25 Q2	7.09M
25 Q1	3.03M
24 Q4	4.76M
24 Q3	1.14M
24 Q2	2.63M
24 Q1	945.73K

Employee Count

NRXS Employee Count by quarter
Period	Employee Count
2025	24
2024	21
2023	19

Free Cash Flow Yield

NRXS Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-8.1%
Sep 26	-7.8%
Aug 26	-7.75%
Aug 26	-7.56%
Aug 26	-7.38%
Aug 26	-7.82%
Jul 26	-8.87%
Jul 26	-8.16%
Jul 26	-8.22%
Jul 26	-7.77%
Jul 26	-7.86%
Jun 26	-7.63%
Jun 26	-7.76%
Jun 26	-8.28%
Jun 26	-8.11%
May 26	-7.48%
May 26	-7.52%
May 26	-7.05%
May 26	-8.68%
May 26	-8.81%
Apr 26	-9.05%
Apr 26	-9.86%
Apr 26	-10.4%
Apr 26	-9.82%
Mar 26	-10.31%
Mar 26	-9.34%
Mar 26	-9.27%
Mar 26	-11.14%
Feb 26	-10.6%
Feb 26	-11.5%
Feb 26	-12.95%
Feb 26	-14.62%
Jan 26	-15.03%
Jan 26	-13.09%
Jan 26	-13.92%
Jan 26	-13.09%
Jan 26	-14.26%
Dec 25	-16.22%
Dec 25	-19.75%
Dec 25	-24%
Dec 25	-23.82%
Nov 25	-22.88%
Nov 25	-24.27%
Nov 25	-27.18%
Nov 25	-28.89%
Oct 25	-26.98%
Oct 25	-21.02%
Oct 25	-24.22%
Oct 25	-24.62%
Oct 25	-23.07%
Sep 25	-24.54%
Sep 25	-28.89%
Sep 25	-30.32%
Sep 25	-30.19%
Aug 25	-28.89%
Aug 25	-29.71%
Aug 25	-30.45%
Aug 25	-34.86%
Aug 25	-34.3%
Jul 25	-30.96%
Jul 25	-32.73%
Jul 25	-35.73%
Jul 25	-33.24%
Jun 25	-34.58%
Jun 25	-33.76%
Jun 25	-37.45%
Jun 25	-32.86%
May 25	-31.41%
May 25	-28.3%
May 25	-38.12%
May 25	-44.27%
May 25	-38.16%
Apr 25	-36.29%
Apr 25	-55.34%
Apr 25	-49.46%
Apr 25	-47.86%
Mar 25	-42.16%
Mar 25	-38.33%
Mar 25	-46.52%
Mar 25	-45.88%
Feb 25	-46.09%
Feb 25	-43.5%
Feb 25	-41.69%
Feb 25	-39.48%
Jan 25	-40.19%
Jan 25	-32.21%
Jan 25	-35.25%
Jan 25	-40.35%
Jan 25	-41.52%
Dec 24	-41.35%
Dec 24	-41.87%
Dec 24	-40.51%
Dec 24	-37.35%
Nov 24	-33.8%
Nov 24	-39.96%
Nov 24	-38.69%
Nov 24	-50.78%
Nov 24	-47.06%
Oct 24	-41.31%
Oct 24	-40.36%

Price to Sales

NRXS Price to Sales by quarter
Period	Price to Sales
Sep 26	13.09
Sep 26	13.59
Aug 26	13.68
Aug 26	14.02
Aug 26	14.36
Aug 26	18.13
Jul 26	15.98
Jul 26	17.39
Jul 26	17.26
Jul 26	18.26
Jul 26	18.05
Jun 26	18.59
Jun 26	18.28
Jun 26	17.13
Jun 26	17.49
May 26	18.95
May 26	18.87
May 26	20.12
May 26	20.87
May 26	20.56
Apr 26	20
Apr 26	18.37
Apr 26	17.41
Apr 26	18.45
Mar 26	17.56
Mar 26	19.39
Mar 26	20.15
Mar 26	16.78
Feb 26	17.63
Feb 26	16.25
Feb 26	14.42
Feb 26	12.78
Jan 26	12.43
Jan 26	14.28
Jan 26	13.43
Jan 26	14.28
Jan 26	13.1
Dec 25	11.52
Dec 25	9.46
Dec 25	7.79
Dec 25	7.84
Nov 25	8.17
Nov 25	7.7
Nov 25	6.87
Nov 25	6.73
Oct 25	7.2
Oct 25	9.24
Oct 25	8.02
Oct 25	7.89
Oct 25	8.42
Sep 25	7.92
Sep 25	6.73
Sep 25	6.41
Sep 25	6.44
Aug 25	6.73
Aug 25	6.54
Aug 25	6.38
Aug 25	6.26
Aug 25	6.36
Jul 25	7.04
Jul 25	6.66
Jul 25	6.1
Jul 25	6.56
Jun 25	6.31
Jun 25	6.46
Jun 25	5.82
Jun 25	6.64
May 25	6.94
May 25	7.71
May 25	5.72
May 25	5.15
May 25	5.98
Apr 25	6.29
Apr 25	4.12
Apr 25	4.61
Apr 25	4.77
Mar 25	5.41
Mar 25	5.95
Mar 25	6.14
Mar 25	6.22
Feb 25	6.2
Feb 25	6.56
Feb 25	6.85
Feb 25	7.23
Jan 25	7.1
Jan 25	8.87
Jan 25	8.1
Jan 25	7.08
Jan 25	6.88
Dec 24	6.91
Dec 24	6.82
Dec 24	7.05
Dec 24	7.64
Nov 24	8.45
Nov 24	9.31
Nov 24	9.62
Nov 24	7.33
Nov 24	7.91
Oct 24	9.01
Oct 24	9.22

Price to Book

NRXS Price to Book by quarter
Period	Price to Book
Sep 26	10.33
Sep 26	10.73
Aug 26	10.8
Aug 26	11.07
Aug 26	11.34
Aug 26	13.51
Jul 26	11.91
Jul 26	12.95
Jul 26	12.86
Jul 26	13.6
Jul 26	13.45
Jun 26	13.85
Jun 26	13.62
Jun 26	12.76
Jun 26	13.03
May 26	14.11
May 26	14.06
May 26	14.99
May 26	21.91
May 26	21.59
Apr 26	21
Apr 26	19.29
Apr 26	18.28
Apr 26	19.37
Mar 26	18.44
Mar 26	20.36
Mar 26	29.66
Mar 26	24.68
Feb 26	25.94
Feb 26	23.91
Feb 26	21.23
Feb 26	18.81
Jan 26	18.29
Jan 26	21.01
Jan 26	19.76
Jan 26	21.01
Jan 26	19.28
Dec 25	16.95
Dec 25	13.92
Dec 25	11.46
Dec 25	11.54
Nov 25	12.02
Nov 25	11.33
Nov 25	10.12
Nov 25	5.09
Oct 25	5.45
Oct 25	6.99
Oct 25	6.07
Oct 25	5.97
Oct 25	6.37
Sep 25	5.99
Sep 25	5.09
Sep 25	4.85
Sep 25	4.87
Aug 25	5.09
Aug 25	4.95
Aug 25	4.83
Aug 25	71.03
Aug 25	72.19
Jul 25	79.98
Jul 25	75.65
Jul 25	69.3
Jul 25	74.5
Jun 25	71.61
Jun 25	73.34
Jun 25	66.12
Jun 25	75.36
May 25	78.83
May 25	87.49
May 25	64.97
May 25	6.69
May 25	7.76
Apr 25	8.16
Apr 25	5.35
Apr 25	5.99
Apr 25	6.19
Mar 25	7.03
Mar 25	7.73

No video analysis for this stock yet. Request one from our team.

News: NRXS

zacks.com · 12 Sep 2026

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

KODK and NRXS are worth watching for their growth.

zacks.com · 14 Aug 2026

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

seekingalpha.com · 11 Aug 2026

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

globenewswire.com · 4 Aug 2026

NeurAxis Expands Payer Coverage with New Policies

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region.

globenewswire.com · 28 Jul 2026

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.